CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Congressional Trades
Whale Activity
- Increased154
- New135
- Held95
- Decreased236
- Closed52
- No prior filing26
| Filer | Shares | Value | Change |
|---|---|---|---|
| FMR LLC | 6.0M | $1.76B | increased |
| BlackRock, Inc. | 3.8M | $1.11B | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.1M | $922.7M | decreased |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.0M | $887.4M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.2M | $645.8M | decreased |
| STATE STREET CORP | 1.9M | $552.8M | increased |
| Invesco Ltd. | 1.9M | $546.5M | decreased |
| HARRIS ASSOCIATES L P | 1.4M | $416.1M | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 1.3M | $382.9M | decreased |
| ARIEL INVESTMENTS, LLC | 1.2M | $352.0M | decreased |
| EARNEST PARTNERS LLC | 1.1M | $320.7M | decreased |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 1.0M | $299.1M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| FOSTER JAMES CDirector · Director | Sale | −24.0K | $350.00 | $8.4M | Oct 22, 2026 | Form 4 ↗ |
| Parisotto Shannon MCEVP, Disc & Safety Assessment | Sale | −2,156 | $344.41 | $743K | Oct 21, 2026 | Form 4 ↗ |
| Parisotto Shannon MCEVP, Disc & Safety Assessment | Sale | −981 | $308.44 | $303K | Oct 5, 2026 | Form 4 ↗ |
| Coleman GlennEVP & Chief Financial Officer | Purchase | +10 | $297.43 | $3K | Sep 30, 2026 | Form 4 ↗ |
| FOSTER JAMES CDirector | Sale | −33.6K | $300.00 | $10.1M | Aug 25, 2026 | Form 4 ↗ |
| FOSTER JAMES CDirector | Option exercise | +12.4K | $208.44 | $2.6M | Aug 25, 2026 | Form 4 ↗ |
| FOSTER JAMES CDirector | Option exercise | +21.1K | $194.12 | $4.1M | Aug 25, 2026 | Form 4 ↗ |
| Girshick BirgitChief Executive Officer · Director | Gift | −528 | $0.00 | $0 | Aug 19, 2026 | Form 4 ↗ |
| Parisotto Shannon MCEVP, Disc & Safety Assessment | Sale | −2,039 | $294.12 | $600K | Aug 19, 2026 | Form 4 ↗ |
| Parisotto Shannon MCEVP, Disc & Safety Assessment | Option exercise | +2,039 | $194.12 | $396K | Aug 19, 2026 | Form 4 ↗ |
| Andrews Nancy CDirector | Sale | −573 | $285.24 | $163K | Aug 18, 2026 | Form 4 ↗ |
| Andrews Nancy CDirector | Option exercise | +573 | $164.30 | $94K | Aug 18, 2026 | Form 4 ↗ |
| Girshick BirgitChief Executive Officer · Director | Sale | −6,500 | $279.90 | $1.8M | Aug 11, 2026 | Form 4 ↗ |
| Girshick BirgitChief Executive Officer · Director | Option exercise | +6,500 | $179.66 | $1.2M | Aug 11, 2026 | Form 4 ↗ |
| Parisotto Shannon MCEVP, Disc & Safety Assessment | Sale | −3,714 | $279.66 | $1.0M | Aug 11, 2026 | Form 4 ↗ |
| Parisotto Shannon MCEVP, Disc & Safety Assessment | Option exercise | +3,714 | $179.66 | $667K | Aug 11, 2026 | Form 4 ↗ |
| LaPlume Joseph WEVP, Corp Strategy & Develop | Gift | −257 | $0.00 | $0 | Aug 10, 2026 | Form 4 ↗ |
| FOSTER JAMES CDirector | Sale | −28.7K | $275.00 | $7.9M | Aug 10, 2026 | Form 4 ↗ |
| FOSTER JAMES CDirector | Option exercise | +28.7K | $179.66 | $5.2M | Aug 10, 2026 | Form 4 ↗ |
| Knell Michael GunnarSVP, Finance and CAO | Sale | −736 | $258.53 | $190K | Aug 6, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Fidelity Contrafund | 1.8M | $410.0M | 0.23% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.5M | $347.0M | 0.02% | Jun 30, 2026 |
| Oakmark Select Fund HARRIS ASSOCIATES INVESTMENT TRUST | 1.5M | $339.7M | 4.08% | Jun 30, 2026 |
| Allspring Special Mid Cap Value Fund ALLSPRING FUNDS TRUST | 1.5M | $329.6M | 2.45% | Jun 30, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 1.2M | $283.0M | 0.02% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 1.1M | $250.6M | 0.13% | Jun 30, 2026 |
| Invesco S&P 500 Equal Weight ETF Invesco Exchange-Traded Fund Trust | 1.0M | $232.8M | 0.24% | Jul 31, 2026 |
| Fidelity 500 Index Fund Fidelity Concord Street Trust | 625.3K | $180.2M | 0.02% | Aug 31, 2026 |
| VANGUARD SMALL-CAP VALUE INDEX FUND VANGUARD INDEX FUNDS | 699.8K | $158.7M | 0.23% | Jun 30, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 662.6K | $150.3M | 0.02% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list CRL's shares (CUSIP 159864107), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- T. Rowe Price Associates, Inc.SCHEDULE 13G · passive (13G) · 3.0M shares6.3%
Nov 16, 2026 · ↗ - Invesco Ltd.SCHEDULE 13G/A · passive (13G) · 1.9M shares3.9%
Nov 10, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 5.9M shares12.4%
Nov 5, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 5.9M shares12.4%
Nov 5, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 4.9M shares10.2%
Sep 8, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 4.9M shares10.2%
Sep 8, 2026 · ↗ - Invesco Ltd.SCHEDULE 13G · passive (13G) · 3.0M shares6.2%
Aug 13, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 4.2M shares8.8%
Aug 6, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 4.2M shares8.8%
Aug 6, 2026 · ↗ - Invesco Ltd.SCHEDULE 13G/A · passive (13G) · 2.4M shares4.9%
May 6, 2026 · ↗
Corporate Lobbying
- CAPITOL HILL CONSULTING GROUPCHARLES RIVER LABORATORIES INTERNATIONAL, INC · 2026 Q3 · HCR, FOO, PHA$80K
Filing ↗ - CAPITOL HILL CONSULTING GROUPCHARLES RIVER LABORATORIES INTERNATIONAL, INC · 2026 Q2 · HCR, FOO, PHA$70K
Filing ↗ - CAPITOL HILL CONSULTING GROUPCHARLES RIVER LABORATORIES INTERNATIONAL, INC · 2026 Q1 · HCR, FOO, PHA$70K
Filing ↗ - CAPITOL HILL CONSULTING GROUPCHARLES RIVER LABORATORIES INTERNATIONAL, INC · 2026 Q1 · HCR, FOO, PHA—
Filing ↗ - K&L GATES, LLPCHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2021 Q1—
Filing ↗
Government Contracts
No federal contract awards found for CHARLES RIVER LABORATORIES INTERNATIONAL, INC..
U.S. Patents
No USPTO patent applications found for CHARLES RIVER LABORATORIES INTERNATIONAL, INC..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B |
| Operating income | $25.2M | $227.3M | $617.3M | $651.0M | $589.9M |
| Net income | -$144.3M | $22.2M | $474.6M | $486.2M | $391.0M |
| Diluted EPS | -$2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
| Operating cash flow | $737.6M | $734.6M | $683.9M | $619.6M | $760.8M |
| Cash and equivalents | $213.8M | $194.6M | $276.8M | $233.9M | $241.2M |
| Total assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B |
| Total liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B |
| Shareholders' equity | $3.16B | $3.46B | $3.60B | $2.98B | $2.53B |
As CHARLES RIVER LABORATORIES INTERNATIONAL, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 18, 2026 ↗
Stock Splits
No stock splits in CRL's price history.
Material Events (8-K)
- 8-K · Items 7.01, 9.01Reg FD disclosureNov 9, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsNov 4, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureSep 24, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 5, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteMay 11, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 7, 2026
EDGAR ↗










